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Abstract
Major depressive disorder (MDD), one of the most frequently encountered forms of mental illness 
and a leading cause of disability worldwide1, poses a major challenge to genetic analysis. To date 
no robustly replicated genetic loci have been identified 2, despite analysis of more than 9,000 
cases3. Using low coverage genome sequence of 5,303 Chinese women with recurrent MDD 
selected to reduce phenotypic heterogeneity, and 5,337 controls screened to exclude MDD, we 
identified and replicated two genome-wide significant loci contributing to risk of MDD on 
chromosome 10: one near the SIRT1 gene (P-value = 2.53×10−10) the other in an intron of the 
LHPP gene (P = 6.45×10−12). Analysis of 4,509 cases with a severe subtype of MDD, 
melancholia, yielded an increased genetic signal at the SIRT1 locus. We attribute our success to 
the recruitment of relatively homogeneous cases with severe illness.
The existence and number of subtypes of depression have been debated over the past 100 
years. The current consensus is that depression may be a collection of partly distinct 
diseases, with overlapping causal pathways. This etiologic heterogeneity might therefore 
substantially reduce the power of genetic association studies and hence explain the failure to 
find genetic risk loci 3. For example, there may be cases of MDD of largely environmental 
origin whose presence reduces power to detect genetic effects. Genetic risk factors for mild 
depressive syndromes may not be entirely the same as those for more severe cases 4.
For these reasons, we investigated the genetic basis of MDD in subjects for whom known 
sources of phenotypic and genetic heterogeneity were minimized and known risk factors 
documented. The CONVERGE (China, Oxford and Virginia Commonwealth University 
Experimental Research on Genetic Epidemiology) consortium recruited 11,670 Han 
Chinese women through a collaboration involving 58 hospitals in China. We studied women 
only because about 45% of the genetic liability to MDD is not shared between sexes 5,6. In 
an attempt to obtain severe cases of MDD, we recruited only recurrent cases (mean number 
of episodes was 5.6).
We used low coverage sequencing to genotype our sample7. Whole genome sequence was 
acquired to a mean depth of 1.7× (95% CIs 0.7-4.3) per individual from which 32,781,340 
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SNP sites were identified. After applying stringent quality controls (Supplemental Methods), 
we obtained 10,640 samples (5,303 cases of MDD, 5,337 controls) and 6,242,619 SNPs for 
inclusion in GWAS. We compared genotypes from the low coverage sequencing to 
genotypes called with 10× coverage sequence and to genotypes called from genotyping 
arrays and a mass spectrometer platform. The mean percentage concordance between 
genotypes from nine individuals with both low and 10X coverage across all sites was 98.1% 
(Supplemental Table 1). We compared imputed genotypes to those acquired for 72 
individuals using an array and to 21 SNPs genotyped on all individuals with the 
MassARRAY™ system mass spectrometer (Supplemental Methods). Overall concordance 
was 98.0% (Supplemental Tables 2 and 3).
Genetic association analysis was carried out with a linear mixed model with a genetic 
relatedness matrix (GRM) as a random effect and principal components from eigen-
decomposition of the GRM as fixed effects (Methods, Supplemental Methods)8,9. Figure 1a 
and Extended Data Figure 1 show the Manhattan and quantile-quantile plots respectively for 
the analysis. The genomic-control inflation factor (λ, the ratio of the observed median χ2 to 
that expected by chance) for association with MDD was 1.070 (for common SNPs > 2 %, λ 
= 1.074). The adjusted measure for sample size to that of 1,000 cases and 1,000 controls 
(λ1000) was 1.013.
Two loci exceeded genome-wide significance in association with MDD: one 5′ to the 
sirtuin1 (SIRT1) gene on chromosome 10 (SNP = rs12415800, chromosome 10:69624180, 
minor allele frequency (MAF) = 45.2%, P = 1.92×10−8, Figure 1b) and the other in an intron 
of the phosphorlysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP) gene 
(SNP = rs35936514, chromosome 10:126244970, MAF = 26.0%, P = 1.27×10−8, Figure 1c). 
All SNPs with P-values of association <10−6 with MDD are listed in Supplemental Table 4.
We checked the accuracy of the imputed genotypes at 12 SNPs with P < 1×10−5, by re-
genotyping the CONVERGE samples using a MassARRAY™ system mass spectrometer, 
thereby confirming their association with MDD. Extended Data Table 1 shows that the 
correlation between the two assays was high (mean R2 = 0.984), and the odds ratios for the 
two genome-wide significant SNPs assessed by the two methods were almost identical with 
highly overlapping confidence intervals (rs12415800 odds ratios: 1.167 vs 1.167; 
rs35936514 odds ratios: 0.845 vs 0.842).
We replicated the associations by genotyping the same 12 SNPs in a separate Han Chinese 
cohort of 3,231 cases with recurrent MDD, and 3,186 controls (both sexes). Two SNPs at 
the peaks of association for SIRT1 and LHPP loci (rs12415800 and rs35936514 
respectively) for MDD in CONVERGE were significantly associated with MDD (Table 1). 
Analysis of the combined samples gave P-values for association with MDD at these two 
SNPs of 2.53×10−10 and 6.45×10−12, respectively. Extended Data Table 2 shows the 
genotype distribution and p-values for tests of violation of Hardy-Weinberg Equilibrium 
(HWE) in both CONVERGE and the replication cohort at both SNPs.
Comparison with results from the Psychiatric Genomics Consortium (PGC) mega-analysis 
of European studies3 failed to provide robust replication for our top SNPs (Extended Data 
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Figure 2 and Extended Data Table 3). However the proportion of associations in the same 
direction in the two studies exceeded chance expectations (P<0.001), and polygenic risk 
scores from the PGC mega-analysis applied to the CONVERGE samples were of significant 
(P<0.01) but limited predictive value, accounting for 0.1% of MDD risk in CONVERGE 
(Extended Data Table 4). It is unclear to what extent differences in sample ascertainment, 
ethnicity, or other factors contribute to the failure to replicate genetic effects in the PGC 
sample. Notably, variants at our most strongly associated loci are much rarer in European 
populations, where rs12415800 (SIRT1) and rs35936514 (LHPP) have frequencies of 3% 
and 8% respectively, compared to 45% and 26% in CONVERGE.
We considered whether successful mapping of MDD in CONVERGE was attributable to the 
recruitment of a severe, more genetically determined form of the disease. We tested that 
hypothesis by looking within CONVERGE at a particularly severe, and more heritable form 
of MD: melancholia10. Prior research has suggested that MDD patients with melancholia 
have more impairing, recurrent episodes and that risk for MD is increased in the co-twins of 
probands with the melancholic subtype11. This increase is greater in monozygotic than 
dizygotic pairs 11, as would be expected if the subtype were associated with greater genetic 
risk.
In CONVERGE, 85% of cases met DSM-IV melancholia criteria12. We searched for genetic 
association in 9,846 samples (4,509 cases and 5,337 controls) and identified the same two 
loci that exceeded genome-wide significance on chromosome 10. The genomic-control 
inflation factor λ for melancholia was 1.069, and λ1000 was 1.014. Even though the sample 
for melancholia was smaller than for MDD, at the SIRT1 locus the significance of 
association was two orders of magnitude greater than for (top SNP = rs80309727, 
chromosome 10:69617347, MAF = 45.2%, P = 2.95×10−10). Extended Data Figure 3 shows 
the Manhattan plot, quantile-quantile plot and detailed views of the SIRT1 locus associated 
with melancholia. All SNPs with P-values of association <10−6 with melancholia are listed 
in Supplemental Table 5. To determine whether the increased association might have arisen 
by chance, we generated an empirical distribution of odds ratios by randomly selecting 
4,509 cases from the total set and re-analysing the association with each of the genome-wide 
significant variants. We found that the observed value lay on the 98.8 percentile at the SIRT1 
locus, but at the 61.6 percentile at the LHPP locus (Extended Data Figure 4).
Our results indicate that, as others have suggested13, obtaining low sequence coverage of a 
large number of individuals can be an effective way to screen the genome for association 
signals. We were able to genotype more variants than present on typical genotyping arrays 
and our set is larger than publicly available sources for imputation14. The imputation 
pipeline we used employed standard tools, and it is likely that imputation accuracy could be 
improved with further algorithmic research.
MDD is most likely highly polygenic3 and many additional loci remain to be discovered. 
We attribute the discovery and replication of two SNPs associated with MDD in 
CONVERGE to the recruitment of severely ill cases in a population where the disease has a 
relatively low prevalence (e.g., life-time prevalence rate for MDD in China of 3.6% 15 
versus 16.2% in the US 16), at least in part because individuals who report depressive illness 
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in East Asian cultures are more impaired than those in Western cultures17. Consistent with 
this interpretation, 85% of CONVERGE has melancholia, a severe subtype of MDD; 
moreover, mapping melancholia led to significant increase in genetic signal at one locus. 
However, in the absence of replication, this result should be regarded as tentative. Finally 
we note that one of the replicated risk loci lies close to a gene involved in mitochondrial 
biogenesis (SIRT1)18, which, together with our finding that MDD is associated with 
increased amounts of mitochondrial DNA19, suggests an unexpected origin for at least some 
of the phenotypic manifestations of MDD.
Methods
Sample collection
CONVERGE collected cases of recurrent major depression from 58 provincial mental health 
centres and psychiatric departments of general medical hospitals in 45 cities and 23 
provinces of China. Controls were recruited from patients undergoing minor surgical 
procedures at general hospitals (37%) or from local community centres (63%). A sample 
size of 6,000 cases and 6,000 controls was chosen on the basis of evidence available when 
the study was designed (in 2007) of the likely existence of genetic loci with odds ratio of 1.2 
and above. All subjects were Han Chinese women with four Han Chinese grandparents. 
Cases were excluded if they had a pre-existing history of bipolar disorder, psychosis or 
mental retardation. Cases were aged between 30 and 60 and had two or more episodes of 
MDD meeting DSM-IV criteria20 with the first episode occurring between 14 and 50 years 
of age, and had not abused drugs or alcohol before their first depressive episode. All subjects 
were interviewed using a computerized assessment system. Interviewers were postgraduate 
medical students, junior psychiatrists or senior nurses, trained by the CONVERGE team for 
a minimum of one week. The diagnosis of MDD was established with the Composite 
International Diagnostic Interview (CIDI) (WHO lifetime version 2.1; Chinese version), 
which utilized DSM-IV criteria. The interview was originally translated into Mandarin by a 
team of psychiatrists in Shanghai Mental Health Centre, with the translation reviewed and 
modified by members of the CONVERGE team.
The replication sample was obtained from five hospitals in the north of China. Patients were 
diagnosed as having MDD by at least two consultant psychiatrists by DSM-IV criteria. 
Samples were of both sexes, and all four grandparents were Han Chinese. Cases were aged 
between 30 and 60, and had two or more episodes of MDD meeting DSM-IV criteria. 
Exclusion criteria were pregnancy, severe medical conditions, abnormal laboratory baseline 
values, unstable psychiatric features (e.g., suicidal), a history of alcoholism or drug abuse, 
epilepsy, brain trauma with loss of consciousness, neurological illness, or a concomitant 
Axis I psychiatric disorder. Control subjects were recruited from local communities and 
provided information about medical and family histories. Exclusion criteria were a history of 
major psychiatric or neurological disorders, psychiatric treatment or drug abuse, or family 
history of severe forms of psychiatric disorders.
The study protocol was approved centrally by the Ethical Review Board of Oxford 
University (Oxford Tropical Research Ethics Committee) and the ethics committees of all 
participating hospitals in China. All interviewers were mental health professionals who are 
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well able to judge decisional capacity. The study posed minimal risk (an interview and 
saliva sample). All participants provided their written informed consent.
DNA sequencing
DNA was extracted from saliva samples using the Oragene protocol. A barcoded library was 
constructed for each sample. Sequencing reads obtained from Illumina Hiseq machines were 
aligned to Genome Reference Consortium Human Build 37 patch release 5 (GRCh37.p5) 
with Stampy (v1.0.17) 21 using default parameters after filtering out reads containing 
adaptor sequencing or consisting of more than 50% poor quality (base quality <= 5) bases. 
Samtools (v0.1.18)22 was used to index the alignments in BAM format22 and Picardtools 
(v1.62) was used to mark PCR duplicates for downstream filtering. The Genome Analysis 
Toolkit’s (GATK, version 2.6) 23 BaseRecalibrator was then run on the BAM files to create 
base quality score recalibration tables, masking known SNPs and INDELs from dbSNP 
(version 137, excluding all sites added after version 129). Base quality recalibration (BQSR) 
was then performed on the BAM files using GATKlite (v2.2.15)23 while also removing read 
pairs that did not have the “properly aligned segment” bit set by Stampy (1-5% of reads per 
sample).
Calling and imputation of genotypes at SNPs included in GWAS
Variant discovery and genotyping at all polymorphic SNPs in 1000G Phase1 East Asian 
(ASN) reference panel 14 was performed simultaneously using post-BQSR sequencing reads 
from all samples using the GATK’s UnifiedGenotyper (version 2.7-2-g6bda569). Variant 
quality score recalibration was then performed on these sites using the GATK’s 
VariantRecalibrator (version 2.7-2-g6bda569) and the biallelic SNPs from 1000G Phase1 
ASN samples as a true positive set of variants. A sensitivity threshold of 90% to SNPs in the 
1000G Phase1 ASN panel was applied for SNP selection for imputation after optimizing for 
Transition to Transversion (TiTv) ratios in SNPs called. Genotype likelihoods (GLs) were 
calculated at selected sites using a sample-specific binomial mixture model implemented in 
SNPtools (version 1.0) 24, and imputation was performed at those sites without a reference 
panel using BEAGLE (version 3.3.2) 25. A second round of imputation was performed with 
BEAGLE on the same GLs, but only at biallelic SNPs polymorphic in the 1000G Phase 1 
ASN panel using the 1000G Phase 1 ASN haplotypes as a reference panel (see 
Supplemental Methods). A final set of allele dosages and genotype probabilities was 
generated from these two datasets by replacing the results in the former with those in the 
latter at all sites imputed in the latter. We then applied a conservative set of inclusion 
threshold for SNPs for genome-wide association study (GWAS): a) p-value for violation 
HWE > 10−6, b) Information score > 0.9, c) MAF in CONVERGE > 0.5% to arrive at the 
final set of 6,242,619 SNPs for GWAS.
Sample selection for GWAS
Using both processed sequencing data and imputed dosages at SNPs that passed quality 
control, we assessed the sequencing and imputation quality of all 11,670 samples whose 
genomic variants we imputed. We first assessed the number of private variants called from 
processed sequencing data of all samples, and excluded 117 samples with excess number of 
private variants in the genic regions of their nuclear genome. Also using processed 
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sequencing data, we excluded a further 90 samples with excess number of heteroplasmic 
sites in their mitochondrial genome. Both filters were applied to exclude DNA samples that 
were likely contaminated. Using imputed data at all sites in the rest of the 11,463 samples, 
we excluded 29 samples for low imputation quality (maximum genotype probability < 0.9) 
in more than 10% of imputed sites. Using a subset of 399,211 tagging SNPs (MAF >1%, LD 
R2 < 0.5, all known in 1000G Phase 1 ASN Panel) across all autosomes, we assessed the 
pairwise identity by state (IBS) between all remaining samples, and excluded 392 samples 
for being likely first-degree relatives. Finally, we excluded 590 samples who had incomplete 
phenotype information from the phenotyping interviews to arrive at the final 10,640 samples 
for GWAS. These analyses and filters are detailed in Supplemental Methods.
GWAS using linear mixed model and liability score estimates
We performed GWAS one chromosome at a time, with a mixed-linear model including a 
genetic relationship matrix (GRM) constructed from SNPs in the tagging set other than those 
on the chromosome being studied. This method is implemented in Factored Spectrally 
Transformed Linear Mixed Models (FastLMM version 2.06.20130802). Manhattan plots 
and quantile-quantile plots of the log10 of P-values of the GWAS were generated with 
custom code in R26. Genomic-control inflation factor lambda was calculated using custom 
code in R26.
Replication and joint analyses
We genotyped the replication sample on a MassARRAY™ system mass spectrometer. 
TYPER4.0 was used to assess the reliability of genotype calls generated by SpectroREAD 
from the mass spectra. Default genotype call inclusion criteria were used. To perform the 
association analysis with MDD case-control status at these 12 sites in the replication sample, 
we obtained effect sizes for discovery from logistic regression with PC correction, and then 
for replication from logistic regression, and then performed fixed-effects meta-analysis.
Polygenic risk profiling and binomial sign-test
Single SNP association results were obtained from the Psychiatric Genetics Consortium 
(PGC) study of MDD3. Prior to analysis, SNPs were lifted-over to GRCh37/hg19 
coordinates and excluded if (a) monomorphic in either European (N = 379) or East Asian (N 
= 286) populations from the 1000 Genomes Project Phase 1 reference data 14 or (b) absent 
from the filtered CONVERGE dataset. To construct the PGC-trained polygenic score, we 
initially selected autosomal SNPs with statistical imputation information (INFO) greater 
than 0.9 and MAF greater than 1% in both studies, and performed subsequent LD-based 
“clumping” to remove markers from highly-correlated SNP pairs (pairwise R2 > 0.2 in East 
Asians, 500kb window) while preferentially retaining SNPs with smaller PGC P-values. 
Using the resultant SNP set, we constructed polygene scores based on varying P-value 
thresholds (10−6, 10−5, 10−4, 10−3, 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, and 1) as previously 
described 28 We assessed the predictive value of polygenic scores in a genetically unrelated 
subset of CONVERGE (with pairwise relatedness less than 0.1) by logistic regression, 
adjusting for ancestry principal components (2) demonstrating significant association with 
MDD status. The estimated variance in MDD risk accounted for the polygenic score is given 
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by Nagelkerke’s R2. Using the same P-value thresholds, we tabulated the number of 
independent SNPs with the same direction of allelic effect in the PGC results as observed in 
CONVERGE. Filtering criteria for SNPs was INFO score greater than 0.9 in CONVERGE 
and MAF greater than 1% in both studies, and an analogous LD-clumping procedure was 
performed (pairwise R2 > 0.2 in Europeans, 500kb window). A one-sided binomial sign test 
was used to assess whether this observed fraction was significantly greater than expected by 
chance.
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Extended Data
Extended Data Figure 1: 
Quantile quantile plots for major depressive disorder.
Quantile-quantile plot of GWAS for MDD using the Mixed-Linear-Model with exclusion of 
chromosome marker is on (MLMe) method implemented in FastLMM on 10,640 samples 
(5,303 cases, 5,337 controls), genomic inflation factor lambda (λ) = 1.070, rescaled for an 
equivalent study of 1,000 cases and 1,000 controls (λ1000) = 1.013.
Page 8
Nature. Author manuscript; available in PMC 2016 January 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Extended Data Figure 2: 
Forest plots of estimated SNP effects in CONVERGE and PGCMDD1 studies.
This figure presents the association odds ratios (OR) at 12 SNPs in CONVERGE and the 
best available proxy SNPs in PGC MDD (pairwise R2 >0.6, 500kb window; the proxy SNP 
is marked by “*”). We present the alternative allele frequency (freq), odds ratio (or) with 
respect to the alternative allele, standard error of odds ratio (se) and P values of association 
(pval) for the following analyses (study): primary association analysis with a linear-mixed 
model using imputed allele dosages in 10,640 samples in CONVERGE (pri); validation 
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analysis with logistic regression model with PCs as covariates using genotypes from 
Sequenom on 9,921 samples in CONVERGE (sqnm); association with MDD with a logistic 
regression model in replication cohort of 6,417 samples using genotypes from Sequenom 
(repli); joint association analysis with MDD with a logistic regression model using imputed 
allele dosages in CONVERGE and genotypes from Sequenom in replication cohort (17,057 
samples in total, joint).
Extended Data Figure 3: 
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Manhattan and quantile quantile plots for melancholia.
(a) Manhattan plot of GWAS for melancholia using the Mixed-Linear-Model with exclusion 
of chromosome marker is on (MLMe) method implemented in FastLMM on 9,846 samples 
(4,509 cases, 5,337 controls). (b) Quantile-quantile plot of GWAS for melancholia, genomic 
inflation factor lambda (λ) = 1.069, rescaled for an equivalent study of 1,000 cases and 
1,000 controls (λ1000) = 1.014. (c) Regional association plot on GWAS hit on chromosome 
10 focusing on top SNP rs80309727 at 5′ of SIRT1 gene, generated with LocusZoom.
Extended Data Figure 4: 
Empirical estimation of the odds ratio increases due to the removal of cases not falling under 
the diagnostic class of melancholia from an association analysis with major depression.
The figures show the empirical distributions of the odds ratios for association with each of 
two SNPs (rs79804696, rs35936514), after removing a random set of 796 samples, equal to 
the number of cases of MDD not diagnosed as being melancholic. The horizontal axis is the 
odds ratio for each analysis, and the vertical axis the frequency of occurrence of the odds 
ratio in 10,000 analyses. The vertical red line is the observed odds ratio after removing cases 
of MDD not diagnosed as melancholic.
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Extended Data Table 2:
Genotype distribution and p-values for violation of 
Hardy-Weinberg Equilibrium in CONVERGE and 
replication cohorts
MDD
Disease State SNP
CONVERGE Replication Cohort
HomRef/Het/HomAlt HWE P-value HomRef/Het/HomAlt HWE P-value
All
rs12415800 2151/5301/3169 0.445 1212/3037/1920 0.857
rs35936514 705/4054/5794 0.919 422/2400/3398 0.974
Cases
rs12415800 1178/2626/1490 0.741 654/1538/918 0.829
rs35936514 318/1919/3027 0.549 190/1136/1783 0.627
Controls
rs12415800 973/2675/1679 0.106 558/1499/1002 0.971
rs35936514 387/2135/2767 0.389 232/1264/1615 0.503
This table shows the number of samples with the homozygous reference genotype (HomRef), heterozygous genotypes 
(Het), and homozygous alternative genotype (HomAlt), as well as p-values for violation of Hardy-Weinberg equilibrium 
(HWE) for both CONVERGE study samples and the replication cohort from North China at the top SNPs rs12415800 in 
the SIRT1 locus and rs35936514 in the LHPP locus from the GWAS on MDD. The top two rows show these measures for 
all samples in both the CONVERGE and replication study, the next two rows show that for just cases in CONVERGE and 
the replication cohort, and the last two shows show that for just the controls. The genotype distributions for CONVERGE 
are obtained from hard-called genotypes from maximum imputed genotype probabilities at for each sample at each of the 
two sites. As a genotype will not be called if the maximum genotype probability at a site is lower than 0.9 for any single 
sample, the total number of CONVERGE samples showing called HomRef/Het/HomAlt genotypes does not equal 10,640 
for either SNP. For rs12415800, 19 (9 cases, 10 controls) samples have no genotype calls due to maximum genotype 
probability being smaller than 0.9, giving a total of 10621 CONVERGE (5,294 cases, 5,327 controls) samples with 
genotype calls. For rs35936514, 87 (39 cases, 48 controls) samples have no genotype calls due to maximum genotype 
probability being smaller than 0.9, giving a total of 10,553 (5,264 cases, 5,289 controls) CONVERGE samples with 
genotype calls.
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Extended Data Table 4:
Polygenic risk profiling and binomial sign tests
pT
Polygenic risk profiling Binomial sign test
r 2 P No. SNPs (%) P
0.000001 0.000715 0.0174 3 (100) 0.125
0.00001 8.40E-05 0.415 12 (66.7) 0.194
0.0001 2.57E-05 0.652 62 (58.1) 0.126
0.001 5.87E-06 0.829 481 (53.6) 0.0605
0.01 8.67E-05 0.407 3632 (51.1) 0.101
0.1 0.00142 0.000797 26106 (50.4) 0.126
0.2 0.00126 0.00156 45166 (50.6) 0.00331
0.3 0.00116 0.00246 61074 (50.5) 0.00627
0.4 0.00125 0.00168 74676 (50.5) 0.00335
0.5 0.0011 0.00317 86429 (50.4) 0.00758
1 0.000924 0.00684 124361 (50.3) 0.0116
The table shows the predictive value of a Psychiatric Genetics Consortium (PGC) MDD-trained polygenic risk score on the 
CONVERGE results. Predictive values are shown at varying p-value thresholds (pT) from P<=1×10−6 to 1 (i.e. all results). 
P is the P-value of the prediction and r2 the amount of variance explained (thus the table shows that including all SNPs 
from PGC-MDD explained 0.09% of MDD risk in CONVERGE.). The number of independent SNPs at each threshold is 
presented (No. SNPs); the significance of the observed fraction (%) demonstrating a consistent direction of effect was 
assessed by a one-sided binomial sign test.
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Figure 1. 
Two loci associated with MDD in the CONVERGE sample
(a) Manhattan plot of genome wide association for MDD, (b) association at the SIRT1 region 
on chromosome 10 at 69.6 Mb and (c) the LHPP gene on chromosome 10 at position 126.2 
Mb. The −log10 P-values of imputed SNPs associated with MDD are shown on the left y 
axis. The recombination rates (NCBI Build GRCh37), (light-blue lines), are shown on the 
right y axis. Position in megabases (Mb) is on the x axis. Linkage disequilibrium of each 
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SNP with top SNP, shown in large purple diamond, is indicated by its colour. The plots were 
drawn using LocusZoom29.
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